Loading the company…
Loading the company…
In the last ten years FDA made 2 decisions for Calyxo (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2026 (2). The latest was on 2026-09-15.
| Family | Decisions on record |
|---|---|
| Kidney stone management | 2 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-09-15 | 510(k) | K261447 | CVAC® Aspiration System |
| 2026-03-06 | 510(k) | K260013 | CVAC Image Processor |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Calyxo.
In 2025, Calyxo reported engagement with 3,099 surgeons and other clinicians in the states MedaRep covers, worth $639K in consulting, speaking, meals and travel for its device products, the most in Missouri ($83K to 136). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Missouri ($83K, 136 engaged), Ohio ($63K, 142 engaged), California ($50K, 203 engaged), Florida ($42K, 312 engaged), Maryland ($40K, 51 engaged).